Tilo Grosser
Tilo Grosser
Bielefeld University
Verified email at - Homepage
Cited by
Cited by
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
T Grosser, S Fries, GA FitzGerald
The Journal of clinical investigation 116 (1), 4-15, 2006
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis
TE North, W Goessling, CR Walkley, C Lengerke, KR Kopani, AM Lord, ...
Nature 447 (7147), 1007-1011, 2007
Role of prostacyclin in the cardiovascular response to thromboxane A2
Y Cheng, SC Austin, B Rocca, BH Koller, TM Coffman, T Grosser, ...
Science 296 (5567), 539-541, 2002
Understanding multicellular function and disease with human tissue-specific networks
CS Greene, A Krishnan, AK Wong, E Ricciotti, RA Zelaya, ...
Nature genetics 47 (6), 569-576, 2015
Prostanoids in health and disease
EM Smyth, T Grosser, M Wang, Y Yu, GA FitzGerald
Journal of lipid research 50, S423-S428, 2009
The clinical pharmacology of nonsteroidal antiinflammatory drugs and coxibs.
T Grosser
Applied pharmacokinetics & pharmacodynamics: Principles of therapeutic drug …, 2006
Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival.
FGGA Yang G, Chen L, Grant GR, Paschos G, Song WL, Musiek ES, Lee V ...
Sci Transl Med 8, 324, 2016
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin
T Grosser, S Fries, JA Lawson, SC Kapoor, GR Grant, GA FitzGerald
Circulation 127 (3), 377-385, 2013
Antiinflammatory, antipyretic and analgesic agents
T Grosser, EM Smyth, GA FitzGerald
Goodman and Gilman’s the Pharmacological Basis of Therapeutics (12th Edition …, 2011
Emotion recollected in tranquility: lessons learned from the COX-2 saga
T Grosser, Y Yu, GA FitzGerald
Annual review of medicine 61, 17-33, 2010
Developmental expression of functional cyclooxygenases in zebrafish
T Grosser, S Yusuff, E Cheskis, MA Pack, GA FitzGerald
Proceedings of the National Academy of Sciences 99 (12), 8418-8423, 2002
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs
KN Theken, CR Lee, L Gong, KE Caudle, CM Formea, A Gaedigk, ...
Clinical Pharmacology & Therapeutics 108 (2), 191-200, 2020
Celecoxib pathways: pharmacokinetics and pharmacodynamics
L Gong, CF Thorn, MM Bertagnolli, T Grosser, RB Altman, TE Klein
Pharmacogenetics and genomics 22 (4), 310-318, 2012
Deciphering the human platelet sheddome
KP Fong, C Barry, AN Tran, EA Traxler, KM Wannemacher, HY Tang, ...
Blood, The Journal of the American Society of Hematology 117 (1), e15-e26, 2011
Bioinformatic analysis of circadian gene oscillation in mouse aorta
RD Rudic, P McNamara, D Reilly, T Grosser, AM Curtis, TS Price, ...
Circulation 112 (17), 2716-2724, 2005
Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus
DL Bhatt, T Grosser, J Dong, D Logan, W Jeske, DJ Angiolillo, ...
Journal of the American College of Cardiology 69 (6), 603-612, 2017
The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs
T Grosser, E Ricciotti, GA FitzGerald
Trends in pharmacological sciences 38 (8), 733-748, 2017
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2
S Fries, T Grosser, TS Price, JA Lawson, S Kapoor, S DeMarco, ...
Gastroenterology 130 (1), 55-64, 2006
Analysis of the zebrafish proteome during embryonic development
MB Lucitt, TS Price, A Pizarro, W Wu, AK Yocum, C Seiler, MA Pack, ...
Molecular & Cellular Proteomics 7 (5), 981-994, 2008
Prostanoids and inflammatory pain
L Chen, G Yang, T Grosser
Prostaglandins & other lipid mediators 104, 58-66, 2013
The system can't perform the operation now. Try again later.
Articles 1–20